Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO
Filter by Topic
ASCO 2014 Highlights
ASCO 2014 – Colorectal and Head & Neck Cancer
ASCO 2014 – Immuno-Oncology
ASCO 2014 – Lung Cancer
ASCO 2015 - Lung Cancer
ASCO 2015 Highlights
ASCO 2016 – Lung Cancer
ASCO 2017 – Multiple Myeloma
ASCO 2018 Insights
ASCO 2019
ASCO 2020 Cholangiocarcinoma
ASCO Breast Cancer Symposium
ASCO Quality Care Symposium
ASCO’s 1st Quality Care Symposium
Obesity Ups Death Risk in Premenopausal Patients with ER-Positive, but Not ER-Negative, Breast Cancer
By
Phoebe Starr
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—Obesity increased the risk for breast cancer–associated death in premenopausal patients with estrogen receptor (ER)-positive breast cancer, had little effect in postmenopausal women with ER-positive disease, and had no effect in patients with ER-negative disease, according to results of a large study of 80,000 women with early breast cancer that were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting.
Read Article
Nationwide Adoption of LDCT Screening Will Detect More Early-Stage Lung Cancer, but at Substantial Economic Cost
By
Phoebe Starr
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—The US Preventive Services Task Force (USPSTF) recommends annual low-dose computed tomography (LDCT) lung cancer screening for patients at high risk. What would it mean in terms of cost to society if those recommendations were implemented in the Medicare population?
Read Article
Breakthrough Therapy Designation Program: Reviewing the First-Year Experience
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—The US Food and Drug Administration (FDA) introduced the concept of a breakthrough therapy designation in 2012 to help expedite patient access to new therapies for the treatment of serious or life-threatening diseases.
Read Article
Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses
By
Wayne Kuznar
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—Delaying androgen deprivation therapy (ADT) for at least 2 years did not lead to worse overall survival or prostate cancer–specific survival compared with the initiation of ADT within 3 months of rising prostate-specific antigen (PSA) in men with PSA-only relapse (ie, biochemical relapse) after the primary treatment of prostate cancer with surgery or radiation, according to the results of a large population-based study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing.
Read Article
Patients with Cancer Want but Are Not Getting Information on the Cost of Their Therapy
By
Wayne Kuznar
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Read Article
Getting to Value in Cancer Care: The Time to Have That Conversation Is Now
By
Dana Butler
ASCO 2014 Highlights
,
Cancer Care
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—The question of value in oncology continues to pose challenges for oncologists and payers alike, as the costs of therapy continue to rise and health plans are wrestling with the need to design insurance coverage that promotes value.
Read Article
Oncologists Cite Lack of Resources and Time as Barriers to Addressing Cost Issues with Patients
By
Mark Knight
ASCO 2014 Highlights
,
ASCO
June 2014, Vol 5, No 5
Chicago, IL—Although the majority of oncologists believe that discussing the costs of care with the patient is important, many report a lack of resources available to them to inform cost-benefit decisions and a lack of time to discuss these issues with patients.
Read Article
Impact of p16 Status on Cetuximab + Radiotherapy in Locally Advanced SCCHN
ASCO
,
ASCO 2014 – Colorectal and Head & Neck Cancer
Conference Correspondent
This was a retrospective analysis of the phase 3 IMCL-9815 trial assessing the role of HPV-p16 status in patients with locally advanced SCCHN receiving radiation therapy (RT) plus cetuximab (cetux) or RT alone (Rosenthal DI, et al. ASCO 2014. Abstract 6001).
Read Article
Chemoradiation or Cetuximab/Radiation Versus Induction Chemotherapy Followed by Chemoradiation in Locally Advanced SCCHN
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
Platinum-based chemoradiation therapy (CRT) is the current standard treatment for locally advanced SCCHN, and induction docetaxel/cisplatin/5-fluorouracil (TPF) is superior to cisplatin/5-fluorouracil alone, but it has not been tested when added to concomitant therapy.
Read Article
The E1308 Trial: Reduced-Dose IMRT in HPV-Associated OPSCC After Induction Chemotherapy
ASCO 2014 – Colorectal and Head & Neck Cancer
,
ASCO
Conference Correspondent
In the E2399 trial, HPV+ patients with oropharyngeal squamous cell carcinoma (OPSCC) attained 2-year overall survival (OS) of 95% and progression-free survival (PFS) of 86% when treated with induction chemotherapy (IC) and 70 Gy chemoradiation.
Read Article
Page 9 of 19
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma